Form 4: Celldex Therapeutics Executive Tibor Keler Granted 93,000 Stock Options

Celldex Therapeutics, Inc. (CLDX) Executive VP & CSO Tibor Keler was granted 93,000 incentive stock options with an exercise price of $19.53, vesting over four years.

Summary

• Tibor Keler, Executive VP & CSO of Celldex Therapeutics, Inc. (CLDX), was granted 93,000 incentive stock options.
• The options have an exercise price of $19.53 per share.
• The grant date for these options was June 5, 2025.
• The options begin vesting on June 5, 2026, with 25% vesting on that date, and the remaining portion vesting quarterly in equal amounts over the subsequent 12 quarters (three years).
• The incentive stock options are set to expire on June 5, 2035.
• This grant was made by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

Sentiment

Score: 6

Explanation: The grant of stock options is a positive for executive alignment and retention, but it's a routine compensation event and not indicative of significant new positive or negative company performance that would dramatically shift sentiment.

Positives

• The grant of incentive stock options to Executive VP & CSO Tibor Keler aligns his financial interests with those of the shareholders, incentivizing long-term company performance and value creation.
• The options are part of a structured and pre-approved equity incentive plan (2021 Omnibus Equity Incentive Plan), indicating a standard and transparent approach to executive compensation.

Future Outlook

The vesting schedule for the granted options indicates a long-term incentive structure for the executive, with options vesting over a four-year period, aligning future performance with compensation and encouraging sustained commitment to the company's success.

Industry Context

The grant of incentive stock options to key executives is a common and widely adopted practice within the biotechnology and pharmaceutical industries. This form of compensation is a crucial component of executive remuneration packages, designed to attract, retain, and motivate top talent by directly linking their financial interests to the long-term success and shareholder value creation of the company.

Comparison to Industry Standards

• The structure of this option grant, including a multi-year vesting schedule, is consistent with typical executive equity compensation practices observed across the biotechnology sector.
• While specific comparable companies or projects are not detailed in this filing, such grants are standard mechanisms used by companies like Amgen, Gilead Sciences, or Regeneron Pharmaceuticals to incentivize their leadership, though the specific number of options and exercise price would vary based on company size, stock price, and compensation philosophy.

Stakeholder Impact

• Shareholders: The option grant aims to align the executive's interests with shareholder value creation, potentially leading to improved long-term performance and increased stock value.
• Employees: While this specific filing pertains to an executive, equity incentives are generally part of broader compensation strategies that can positively impact overall employee morale and retention by demonstrating a commitment to performance-based rewards.

Next Steps

• Continued vesting of the granted options over the next four years, subject to the executive's continued employment with Celldex Therapeutics.

Key Dates

Keywords

Celldex Therapeutics, CLDX, Tibor Keler, Form 4, SEC filing, insider transaction, stock options, executive compensation, equity incentive plan